Avery Dennison Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated November 20, 2007, discloses a material definitive agreement and the completion of a public securities offering by Avery Dennison Corporation. The filing details the entry into an Underwriting Agreement on November 14, 2007, and the subsequent completion of the offering on November 20, 2007.
Key Financial Metrics
- Offering Size: 8,000,000 Corporate HiMEDS Units with an aggregate principal amount of $400 million.
- Net Proceeds: Approximately $387 million.
- Over-Allotment Option: Underwriters hold a 30-day option to purchase up to an additional 800,000 HiMEDS Units.
- Instrument Structure: Each HiMEDS Unit ($50 stated amount) consists of a purchase contract for common stock (settling no later than November 15, 2010) and a 5% interest in $1,000 principal amount of 5.350% Senior Notes due 2020.
- Contract Adjustments: Holders receive quarterly payments at a rate of 2.525% per year of the $50 stated amount, subject to deferral rights.
Material Changes
The primary material change is the creation of a direct financial obligation through the issuance of the HiMEDS Units and the underlying Senior Notes. The Notes are pledged as collateral to secure the obligation to purchase common stock under the purchase contracts. The filing does not provide comparative financial data (revenue, profit, or margins) as this is a transaction-specific report rather than a periodic financial statement.
Outlook, Risks, and Contingencies
- Future Obligations: The company has an obligation to deliver shares of common stock upon the purchase contract settlement date (no later than November 15, 2010).
- Remarketing: The Notes are subject to remarketing prior to the settlement date pursuant to a future Remarketing Agreement.
- Deferral Risk: The company retains the right to defer quarterly contract adjustment payments.
- Underwriting: The offering was managed by J.P. Morgan Securities Inc. and Citigroup Global Markets Inc.
Investor Verification Checklist
- Verify the exact number of shares of common stock to be issued per HiMEDS Unit upon settlement in 2010.
- Review the specific terms of the deferral right regarding the 2.525% quarterly contract adjustment payments.
- Confirm the status of the 30-day over-allotment option and whether it was exercised.
- Examine the attached Indenture and Purchase Contract for covenants and restrictions on the Senior Notes.
- Assess the impact of the $387 million net proceeds on the company's liquidity and debt-to-equity ratio.